Postpartum depression pill gets approval in a 1st for Canada – National
Health Canada has approved the first drug designed to treat postpartum depression. Zuranolone, sold under the brand name Zurzuvae, is...
Approval
KFF/Washington Post Poll Looks at Parents’ Trust in Children’s Health Content on Social Media, And Unfounded Claims About Abortion Pill Safety Follow FDA Approval of Generic Version – The Monitor
VOLUME 33 October 23, 2025 Summary This volume highlights the latest release from the KFF/The Washington Post Survey of Parents,...
Biogen’s ZURZUVAE Wins EU Approval for Postpartum Depression
Biogen (NASDAQ:BIIB) has received European Commission (EC) approval for ZURZUVAE® (zuranolone), marking...
RWJBarnabas Health Children’s Health Network Academic Cleft Palate Program Earns Approval
The Bristol-Myers Squibb Children’s Hospital and Rutgers Robert Wood Johnson Medical School Program Approved for Five-Year PeriodAditi Kanth, MD, a...
